文献速递胸部肿瘤

PET-Plan研究:局部晚期非小细胞肺癌放化疗中基于影像的靶区缩减

Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial.
PubMed 文献 · Lancet Oncol · 2020-03-12

PET-Plan是一项多中心、开放标签、随机对照试验,比较18F-FDG PET/CT引导(联合选择性淋巴结照射)与单纯PET引导的靶区勾画在局部晚期非小细胞肺癌根治性放化疗中的效果。结果显示PET引导组局部区域进展风险非劣于且低于常规组,毒性未增加。

要点

  • 两组急性3级及以上毒性(食管炎/吞咽困难)发生率均为16%。
  • 基于PET的靶区缩减可行,可能改善局部控制且不增加毒性。

核心结论

  • 在局部晚期非小细胞肺癌根治性放化疗中,基于18F-FDG PET的靶区勾画非劣效于常规PET/CT联合选择性淋巴结照射,且局部区域进展风险更低。

研究设计与样本

  • 多中心、开放标签、随机对照试验(PET-Plan;ARO-2009-09),在奥地利、德国和瑞士24个中心进行。
  • 纳入既往未治疗、不可手术、适合放化疗的局部晚期非小细胞肺癌患者,ECOG体能状态评分小于3。
  • 患者按1:1随机分配至常规靶区组(PET/CT引导+选择性淋巴结照射)或PET引导靶区组(仅PET引导),按中心和UICC分期分层。
  • 两组均计划剂量递增放疗(60-74 Gy,每次2 Gy)并同步铂类化疗。

主要发现

  • 2009年5月13日至2016年12月5日,311例招募患者中205例随机分配(常规组99例,PET引导组106例;意向治疗集),172例按方案治疗(常规组84例,PET引导组88例)。
  • 最常见的急性3级或更严重毒性为食管炎或吞咽困难(常规组16/99例[16%] vs PET引导组17/105例[16%]);最常见的晚期毒性为肺部相关(12/99例[12%] vs 11/105例[10%])。
  • 报告20例可能与研究治疗相关的死亡(常规组7例 vs PET引导组13例)。

关键数值与推荐

  • 放疗剂量60-74 Gy,每次2 Gy,同步铂类化疗。
  • 主要终点局部区域进展时间,符合方案集分析。

临床怎么用

  • 对于适合根治性放化疗的局部晚期非小细胞肺癌患者,可考虑基于18F-FDG PET的靶区缩减以降低局部区域进展风险且不增加毒性。
  • 该策略可能成为标准治疗选择,但需结合中心经验和多学科讨论。

局限性

  • 开放标签设计,患者和研究 staff 未对治疗分配设盲。
  • 报告了20例可能与研究治疗相关的死亡,需进一步评估安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: With increasingly precise radiotherapy and advanced medical imaging, the concept of radiotherapy target volume planning might be redefined with the aim of improving outcomes. We aimed to investigate whether target volume reduction is feasible and effective compared with conventional planning in the context of radical chemoradiotherapy for patients with locally advanced non-small-cell lung cancer. METHODS: We did a multicentre, open-label, randomised, controlled trial (PET-Plan; ARO-2009-09) in 24 centres in Austria, Germany, and Switzerland. Previously untreated patients (aged older than 18 years) with inoperable locally advanced non-small-cell lung cancer suitable for chemoradiotherapy and an Eastern Cooperative Oncology Group performance status of less than 3 were included. Undergoing 18F-fluorodeoxyglucose (18F-FDG) PET and CT for treatment planning, patients were randomly assigned (1:1) using a random number generator and block sizes between four and six to target volume delineation informed by 18F-FDG PET and CT plus elective nodal irradiation (conventional target group) or target volumes informed by PET alone (18F-FDG PET-based target group). Randomisation was stratified by centre and Union for International Cancer Control stage. In both groups, dose-escalated radiotherapy (60-74 Gy, 2 Gy per fraction) was planned to the respective target volumes and applied with concurrent platinum-based chemotherapy. The primary endpoint was time to locoregional progression from randomisation with the objective to test non-inferiority of 18F-FDG PET-based planning with a prespecified hazard ratio (HR) margin of 1·25. The per-protocol set was included in the primary analysis. The safety set included all patients receiving any study-specific treatment. Patients and study staff were not masked to treatment assignment. This study is registered with ClinicalTrials.gov, NCT00697333. FINDINGS: From May 13, 2009, to Dec 5, 2016, 205 of 311 recruited patients were randomly assigned to the conventional target group (n=99) or the 18F-FDG PET-based target group (n=106; the intention-to-treat set), and 172 patients were treated per protocol (84 patients in the conventional target group and 88 in the 18F-FDG PET-based target group). At a median follow-up of 29 months (IQR 9-54), the risk of locoregional progression in the 18F-FDG PET-based target group was non-inferior to, and in fact lower than, that in the conventional target group in the per-protocol set (14% [95% CI 5-21] vs 29% [17-38] at 1 year; HR 0·57 [95% CI 0·30-1·06]). The risk of locoregional progression in the 18F-FDG PET-based target group was also non-inferior to that in the conventional target group in the intention-to-treat set (17% [95% CI 9-24] vs 30% [20-39] at 1 year; HR 0·64 [95% CI 0·37-1·10]). The most common acute grade 3 or worse toxicity was oesophagitis or dysphagia (16 [16%] of 99 patients in the conventional target group vs 17 [16%] of 105 patients in the 18F-FDG PET-based target group); the most common late toxicities were lung-related (12 [12%] vs 11 [10%]). 20 deaths potentially related to study treatment were reported (seven vs 13). INTERPRETATION: 18F-FDG PET-based planning could potentially improve local control and does not seem to increase toxicity in patients with chemoradiotherapy-treated locally advanced non-small-cell lung cancer. Imaging-based target volume reduction in this setting is, therefore, feasible, and could potentially be considered standard of care. The procedures established might also support imaging-based target volume reduction concepts for other tumours. FUNDING: German Cancer Aid (Deutsche Krebshilfe).

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Nestle U, Schimek-Jasch T, Kremp S, et al. Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial. Lancet Oncol. 2020. PMID: 32171429. doi:10.1016/S1470-2045(20)30013-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。